Aurélien Carnot
Aurélien Carnot is an expert in Oncology at Centre Oscar Lambret (France). Aurélien Carnot has authored 42 publications, the most recent in 2026, and is an investigator in 22 clinical trials, 13 of them ongoing. SLR score: 462 (community average: 125). How the SLR is computed.
LeadR Profile
Oncology
Subspecialties: Urology - Pharmacy - Palliative Medicine
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2020 - 2026
Number : 42
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Antiangiogenic therapies in gastric cancer: future directions for 2026 and beyond: an UNICANCER gastrointestinal group (UCGI) perspective. PMID 42385352 — vascular endothelial growth factor a, angiogenesis inhibitors, neoplasms, biomarkers, protein-tyrosine kinases, tyrosine, therapeutics, stomach neoplasms | Cancer Treat Rev | 2026 | 0 |
| Circulating tumor DNA dynamics and clinical outcomes in patients with advanced Colorectal Cancer treated with cetuximab-based induction and maintenance treatment. PMID 41671078 — circulating tumor dna, cetuximab, induction chemotherapy, neoplasms, disease progression, drug therapy, maintenance, therapeutics, colorectal neoplasms, random allocation, dna, chemotherapy | Clin Cancer Res | 2026 | 0 |
| Surgical outcomes after neoadjuvant avelumab with or without chemotherapy for Muscle-Invasive bladder cancer: a Post-Hoc analysis of the aura trial (Oncodistinct-004). PMID 41528535 — urinary bladder, urinary bladder neoplasms, urology, muscles, neoplasms, drug therapy, immunotherapy, cystectomy, chemotherapy | World J Urol | 2026 | 0 |
| Avelumab-based neoadjuvant therapy in patients with muscle-invasive bladder cancer (AURA Oncodistinct-004): a phase 2 multicenter clinical trial. PMID 40413024 — urinary bladder, urinary bladder neoplasms, safety, muscles, neoplasms, drug therapy, immunotherapy, neoadjuvant therapy, therapeutics, chemotherapy | J Immunother Cancer | 2025 | 0 |
| Circulating tumor DNA strongly predicts efficacy of chemotherapy plus immune checkpoint inhibitors in patients with advanced gastro-esophageal adenocarcinoma. PMID 40275077 — circulating tumor dna, neoplasms, adenocarcinoma, drug therapy, immune checkpoint inhibitors, therapeutics, dna, chemotherapy | Commun Med (Lond) | 2025 | 0 |
Clinical Studies 22
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Ongoing Clinical Trials
13 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| AMG 436 as monotherapy and combination therapy in participants with Microsatellite Instability High Mismatch Repair Deficient Solid Tumors 2025-524056-63-00 — dna mismatch repair, microsatellite repeats, neoplasms, therapeutics, microsatellite instability, mmr-deficient, msi-h | Phase 1 | Recruiting | 2026 |
| Roll Over Study for Patients Who Have Completed a Previous Oncology Study with Olaparib 2024-512982-15-00 — pancreatic neoplasms, breast neoplasms, endometrium, ovary, neoplasms, prostate, ovarian neoplasms, breast, prostatic neoplasms, therapeutics | Phase 3 | Not yet recruiting | 2021 |
| DISCUS A Randomised Phase II Study Comparing 3 vs 6 Cycles of Platinum based Chemotherapy Prior to Maintenance Avelumab in Advanced Urothelial Cancer 2024-518244-20-01 — neoplasms, drug therapy, maintenance, chemotherapy, carcinoma | Phase 2 | Active not recruiting | 2022 |
| Pasritamig With Docetaxel vs Docetaxel in Metastatic Castration resistant Prostate Cancer (mCRPC) 2025-522713-29-00 — cells, kallikreins, docetaxel, neoplasms, prostate, prostatic neoplasms, castration, t-lymphocytes | Phase 3 | Recruiting | 2026 |
| Ezabenlimab (BI 754091) and DCFm (docetaxel cisplatin and 5 fluorouracil) followed by chemoradiotherapy for the treatment of stage III anal canal cancer Phase II study 2024-514083-31-00 — cells, docetaxel, neoplasms, fluorouracil, chemoradiotherapy, anal canal, therapeutics, carcinoma | Phase 2 | Recruiting | 2024 |
LeadR Networks
Main global connection map